Cantharidin-Loaded Nanomedicine Modified with Amphiphilic Peptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade
ACS Applied Materials & Interfaces · 2025
DOI: 10.1021/acsami.5c05498 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Yang Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou 510000, China. Hauptthemen laut MEDLINE: Immunogenic Cell Death, Cantharidin, Programmed Cell Death 1 Receptor, Peptides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangzhou Municipal Science and Technology Bureau, National Natural Science Foundation of China, Guangzhou Traditional Chinese Medicine.
Abstract (Originalsprache)
Recent advances in immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1, have transformed cancer treatment. However, their efficacy is often hampered by the immunosuppressive tumor microenvironment (TME). Here, we developed a cantharidin-loaded nanomedicine (CA@TPGS-AmP), composed of D-α-tocopheryl polyethylene glycol succinate (TPGS) and naturally derived amphiphilic peptides (AmP), designed to enhance PD-1 blockade via induction of immunogenic cell death (ICD). In vitro, CA@TPGS-AmP markedly improved the solubility of cantharidin and exhibited superior penetration in 3D tumor spheroids. It effectively triggered key ICD events, including calreticulin (CRT) surface exposure, ATP release, and HMGB1 translocation, thereby promoting dendritic cell (DC) maturation. In vivo, CA@TPGS-AmP significantly augmented the antitumor efficacy of PD-1 therapy in 4T1 orthotopic breast cancer and LLC lung cancer models. Mechanistically, the combination therapy remodeled the TME into an immunostimulatory state by increasing CD8+ T cell infiltration and activation, leading to enhanced tumor suppression compared to monotherapies. These findings support CA@TPGS-AmP as a promising adjunct to PD-1 blockade and highlight the potential of natural product-based nanomedicine in advancing cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou 510000, China.
- Guangzhou University of Chinese Medicine, Guangzhou 510000, China.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528437, China.
ORCID-Profile: Yang Tang
Förderung
- Guangzhou Municipal Science and Technology Bureau
- National Natural Science Foundation of China
- Guangzhou Traditional Chinese Medicine
Zitieren
APA
Tang, Y., Jiang, Q., Chen, R., Wu, S., Luo, Y., Huang, X., Yu, G., & Shao, C. (2025). Cantharidin-Loaded Nanomedicine Modified with Amphiphilic Peptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c05498
Vancouver
Tang Y, Jiang Q, Chen R, Wu S, Luo Y, Huang X, et al. Cantharidin-Loaded Nanomedicine Modified with Amphiphilic Peptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c05498
BibTeX
@article{Tang2025,
author = {Tang, Yang and Jiang, Qun and Chen, Rongli and Wu, Siqi and Luo, Yichang and Huang, Xi and Yu, Guofang and Shao, Cui},
title = {Cantharidin-Loaded Nanomedicine Modified with Amphiphilic Peptides Induce Immunogenic Cell Death to Enhance PD-1 Blockade},
journal = {ACS Applied Materials & Interfaces},
year = {2025},
doi = {10.1021/acsami.5c05498}
}
EUVIMED